By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NeuroDerm Ltd. 



Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209


SEARCH JOBS


Industry
Pharmaceutical






Company News
NeuroDerm (NDRM) Announces Pricing Of A Follow-On Offering Of Ordinary Shares 12/7/2016 8:19:12 AM
NeuroDerm (NDRM) Announces Pricing Of A Follow-On Offering Of Ordinary Shares 12/7/2016 7:48:34 AM
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016 6:21:01 AM
NeuroDerm (NDRM) Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine 12/2/2016 7:18:18 AM
NeuroDerm (NDRM) Announces Third Quarter 2016 Financial Results 11/10/2016 9:01:32 AM
NeuroDerm (NDRM) To Host Third Quarter 2016 Financial Results Conference Call On November 10, 2016 11/1/2016 10:55:53 AM
NeuroDerm (NDRM) Provides Updates On ND0612 Long-Term Safety Trial And Submission Of Marketing Applications 9/29/2016 11:43:54 AM
NeuroDerm (NDRM)’s ND0612 Mini-Pump Delivery System Successfully Used By Parkinson’s Disease Patients In Home Setting 9/23/2016 8:02:44 AM
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016 8:32:22 AM
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016 7:56:30 AM
1234567
//-->